Tag Archives: Pfizer

Generic drug maker Mylan pulls a mini-Pfizer tax inversion

Posted on July 15, 2014 by Alexander Szewczak

Taking a page from Pfizer’s playbook, Mylan is buying Abbott Laboratories’ branded specialty and generics businesses in developed markets outside the U.S..  The $5B deal is structured to result in a tax inversion, with the newly formed merged company to be headquartered in the Netherlands. “We see … Continue reading →

Posted in Pharmaceutical Industry | Tagged , , , | 1 Comment

Pfizer gives up the chase.

Posted on May 26, 2014 by Alexander Szewczak

Pfizer is saying today that it does not intend to extend a firm offer for AstraZeneca, bringing an end to its attempt to acquire the UK drug maker.  AZ shareholders were split on the latest offer, and a stumble by AZ would … Continue reading →

Posted in Pharmaceutical Industry | Tagged , , | Leave a comment

Pfizer raises its bid for AstraZeneca – one last time?

Posted on May 18, 2014 by Alexander Szewczak

Over the weekend, Pfizer finally made an official offer for AstraZeneca,  by raising its bid to $119B (15% higher than the last, unofficial, offer), and increasing the cash portion of the deal from 33% to 45%.  AZ had a market cap of … Continue reading →

Posted in Pharmaceutical Industry | Tagged , , , | Leave a comment

Pfizer is a shark that can’t stop feeding

Posted on May 8, 2014 by Alexander Szewczak

So says John LaMattina, a former head of research at Pfizer: The only way for a shark to survive is to keep going forward. To maintain its leadership, Pfizer will again need to make a major acquisition in the next … Continue reading →

Posted in Pharmaceutical Industry | Tagged , , , , | Leave a comment

Pfizer won’t take no for an answer

Posted on May 5, 2014 by Alexander Szewczak

Amidst several indications that Pfizer will launch a hostile bid for AstraZeneca if necessary, this quote stands out: Asked whether hostile moves could hurt integration of the two companies, Chief Executive Ian Read said, “No, in my opinion, all it … Continue reading →

Posted in Pharmaceutical Industry | Tagged , , , , | Leave a comment

Pfizer’s real strategy is (mostly) tax-minimization

Posted on April 29, 2014 by Alexander Szewczak

   Many observers were initially left scratching their heads over Pfizer’s pursuit of AstraZeneca, a company that has had major pipeline troubles of its own.  As more information has come out, Pfizer’s strategy is beginning to make sense.  They aren’t pursuing an old-style mega … Continue reading →

Posted in Pharmaceutical Industry | Tagged , , , , | 1 Comment

Undeterred, Pfizer continues its mega merger strategy

Posted on April 28, 2014 by Alexander Szewczak

Pfizer continues to stalk AstraZeneca, even as other firms abandon mega mergers.

Posted in Pharmaceutical Industry | Tagged , , | Leave a comment

Pharma megamergers — against the spirit of the times?

Posted on April 23, 2014 by Alexander Szewczak

Here’s more on the Novartis-GSK-Lilly three way deal announced Tuesday.  As WSJ journalist Helen Thomas writes, the megamerger chill of dread felt when rumors of Pfizer’s stalking of AZ came to light last weekend may well be exorcized by this … Continue reading →

Posted in Fixing Big Pharma Research, Pharmaceutical Industry | Tagged , , , , , , | 1 Comment